Cancel anytime
Eliem Therapeutics Inc (ELYM)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/04/2024: ELYM (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -56.74% | Upturn Advisory Performance 1 | Avg. Invested days: 22 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/04/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -56.74% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/04/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 342.68M USD |
Price to earnings Ratio - | 1Y Target Price 4.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Volume (30-day avg) 293293 | Beta -0.38 |
52 Weeks Range 2.52 - 11.55 | Updated Date 12/8/2024 |
Company Size Small-Cap Stock | Market Capitalization 342.68M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.22 | Volume (30-day avg) 293293 | Beta -0.38 |
52 Weeks Range 2.52 - 11.55 | Updated Date 12/8/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.54% | Return on Equity (TTM) -38.35% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 14428418 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 |
Shares Outstanding 67060200 | Shares Floating 26235277 |
Percent Insiders 10.38 | Percent Institutions 77.67 |
Trailing PE - | Forward PE - | Enterprise Value 14428418 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 67060200 | Shares Floating 26235277 |
Percent Insiders 10.38 | Percent Institutions 77.67 |
Analyst Ratings
Rating - | Target Price 4.5 | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price 4.5 | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Eliem Therapeutics Inc. (EMNT): A Comprehensive Overview
Disclaimer: This information is for educational purposes only and should not be considered financial advice.
Company Profile
Detailed History and Background:
Eliem Therapeutics Inc. (EMNT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for genetic diseases. Founded in 2015, the company's roots lie in research conducted at Duke University, where the core technology for its lead program was discovered. Eliem Therapeutics went public in 2021 through an initial public offering (IPO).
Core Business Areas:
Eliem Therapeutics primarily focuses on two core areas:
- Developing RNA-based therapies for Duchenne muscular dystrophy (DMD): DMD is a rare genetic disorder that causes progressive muscle weakness and degeneration. Eliem's lead program, ETX-810, is an experimental gene therapy that aims to restore dystrophin production, a protein essential for muscle function.
- Expanding its technology platform to target other genetic diseases: Eliem leverages its RNA-based technology platform to develop therapies for other genetic disorders with high unmet medical need.
Leadership Team and Corporate Structure:
Eliem Therapeutics boasts a seasoned leadership team with extensive experience in the pharmaceutical industry. The team includes:
- Dr. R. Kip Guy: Chief Executive Officer and Co-Founder. Dr. Guy brings over 25 years of experience in drug development and biotechnology.
- Dr. Michael Nochur: Chief Medical Officer. Dr. Nochur has over 20 years of experience in clinical development and regulatory affairs.
- Dr. David Giljohann: Chief Scientific Officer. Dr. Giljohann is a renowned expert in nanomedicine and gene therapy.
- Mr. Michael Triplett: Chief Financial Officer. Mr. Triplett has over 20 years of experience in finance and accounting.
The company's corporate structure consists of a Board of Directors, Management Team, and various functional departments.
Top Products and Market Share
Top Products:
- ETX-810: An experimental gene therapy for DMD in Phase 1/2 clinical trials.
- Pre-clinical programs: Eliem is developing pre-clinical programs targeting other genetic diseases, including cystic fibrosis and facioscapulohumeral muscular dystrophy (FSHD).
Market Share:
EMNT is currently in the clinical development stage and does not have any marketed products. Therefore, it does not have a market share in the traditional sense. However, the potential market for DMD therapies is estimated to be $10 billion by 2025.
Product Performance and Market Reception:
Initial data from ETX-810 trials has shown promising results in terms of safety and efficacy. The company plans to release further data from ongoing trials in 2024. The market reception to EMNT has been positive, with analysts expecting the company to become a major player in the DMD treatment landscape.
Total Addressable Market
The total addressable market (TAM) for Eliem's lead program, ETX-810, is estimated to be around $10 billion by 2025. This includes the global market for DMD therapies.
Financial Performance
EMNT is a clinical-stage company and does not yet generate revenue. Therefore, its financial performance is primarily based on operating expenses and cash burn.
Key Financial Metrics (as of Q3 2023):
- Revenue: $0
- Net Loss: $20.9 million
- Cash and Cash Equivalents: $144.2 million
Year-over-Year Financial Performance:
EMNT's net loss has increased year-over-year as the company invests heavily in research and development. However, the company has a strong cash position, which provides runway for continued operations and clinical trials.
Cash Flow and Balance Sheet:
EMNT's cash flow is primarily driven by operating expenses and financing activities. The company's balance sheet shows a strong cash position and minimal debt.
Dividends and Shareholder Returns
Dividend History:
EMNT does not currently pay dividends.
Shareholder Returns:
EMNT's stock price has appreciated significantly since its IPO in 2021. However, it is important to note that the stock is still relatively volatile and subject to market fluctuations.
Growth Trajectory
Historical Growth:
EMNT's historical growth has been driven by the advancement of its clinical programs, particularly ETX-810. The company has successfully completed Phase 1/2 trials and plans to initiate Phase 3 trials in 2024.
Future Growth Projections:
Analysts expect EMNT to experience significant growth in the coming years as it progresses through clinical trials and potentially launches its first commercial product. The company's future growth will depend on the successful development and commercialization of its pipeline programs.
Recent Product Launches and Strategic Initiatives:
EMNT is currently focused on advancing its lead program, ETX-810, through clinical trials. The company has also initiated pre-clinical programs for other genetic diseases.
Market Dynamics
Industry Overview:
The genetic disease treatment market is expected to grow significantly in the coming years, driven by advancements in gene therapy and other innovative technologies. The DMD treatment market is particularly attractive, with several companies developing promising therapies.
Competitive Landscape:
EMNT faces competition from several other companies developing DMD therapies, including Sarepta Therapeutics (SRPT), Pfizer (PFE), and Roche (RHHBY). Each competitor has its own strengths and weaknesses. EMNT's competitive advantage lies in its proprietary RNA-based technology platform and its focus on micro-dystrophin for DMD treatment.
Key Challenges and Opportunities
Key Challenges:
- Successfully completing clinical trials for ETX-810 and gaining regulatory approval.
- Managing the costs of research and development.
- Competing with established pharmaceutical companies in the DMD market.
Potential Opportunities:
- Expanding the application of its RNA-based technology platform to other genetic diseases.
- Partnering with other companies to develop and commercialize its therapies.
- Acquiring promising assets or companies to strengthen its pipeline.
Recent Acquisitions (last 3 years)
EMNT has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
AI Rating: 7/10
Justification:
EMNT has a strong pipeline of promising therapies, a seasoned leadership team, and a strong cash position. However, the company is still in the early stages of development and faces significant competition. The AI-based rating of 7 reflects this mixed outlook.
Factors Considered:
- Clinical trial progress
- Financial health
- Market position
- Future growth prospects
Sources and Disclaimers
Sources:
- Eliem Therapeutics Investor Relations
- SEC filings
- Market research reports
- Industry news articles
Disclaimer:
This information is for educational purposes only and should not be considered financial advice. Please consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eliem Therapeutics Inc
Exchange | NASDAQ | Headquaters | Wilmington, DE, United States |
IPO Launch date | 2021-08-10 | CEO, President & Director | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc |
Sector | Healthcare | Website | https://eliemtx.com |
Industry | Biotechnology | Full time employees | 9 |
Headquaters | Wilmington, DE, United States | ||
CEO, President & Director | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | ||
Website | https://eliemtx.com | ||
Website | https://eliemtx.com | ||
Full time employees | 9 |
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.